Positives

• Long COVID patients with the viral persistence theory of their illness have been pursuing sipavibart off-label, hoping a fresh dose of neutralizing antibody might clear residual SARS-CoV-2 antigen; the drug was EMA-approved in 2024 for pre-exposure prophylaxis in severely immunocompromised patients Ema.

Negatives

• One patient who tried sipavibart off-label reported no obvious change in their brain fog, digestive symptoms, or fatigue after a single injection, and concluded the cost (about £1,500) wasn’t justified for them without clearer outcome data Reddit.
• A Swiss user reported that pharmacies could order Kavigale directly from AstraZeneca but the main barrier was finding a doctor willing to prescribe it off-label Reddit.

Hurdles & Side Effects

• EU-approved only for COVID-19 pre-exposure prophylaxis in immunocompromised patients. Any use in Long COVID is off-label Ema.
• One rheumatologist-quoted cost figure is "1,500 British pounds for an injection" — practical access in most health systems means private-pay, off-label prescription from a clinician willing to do it Reddit.
• Do not confuse sipavibart with the older monoclonal Evusheld — sipavibart is a newer drug with a different variant-coverage profile, and forum members citing Evusheld outcomes are describing the wrong drug Ema.